Evidence map›Paper›PMID 25653453›Full record

ArticleJournal of virology2015

Dynamics of the cytotoxic T cell response to a model of acute viral infection.

William S DeWitt, Ryan O Emerson, Paul Lindau, Marissa Vignali, Thomas M Snyder, Cindy Desmarais, Catherine Sanders, Heidi Utsugi, Edus H Warren, Juliana McElrath and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 174 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

William S DeWittAdaptive Biotechnologies, Seattle, Washington, USA.
Ryan O EmersonAdaptive Biotechnologies, Seattle, Washington, USA.
Paul LindauFred Hutchinson Cancer Research Center, Seattle, Washington, USA University of Washington, Seattle, Washington, USA.
Marissa VignaliAdaptive Biotechnologies, Seattle, Washington, USA.
Thomas M SnyderAdaptive Biotechnologies, Seattle, Washington, USA.
Cindy DesmaraisAdaptive Biotechnologies, Seattle, Washington, USA.
Catherine SandersAdaptive Biotechnologies, Seattle, Washington, USA.
Heidi UtsugiFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Edus H WarrenFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Juliana McElrathFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Karen W MakarFred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Anna WaldUniversity of Washington, Seattle, Washington, USA.
Harlan S RobinsAdaptive Biotechnologies, Seattle, Washington, USA Fred Hutchinson Cancer Research Center, Seattle, Washington, USA hrobins@fhcrc.org.
Adaptive Biotechnologies (United States) · USFred Hutch Cancer Center · USUniversity of Washington · US

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
NIAID NIH HHS R56 AI0181860NIGMS NIH HHS T32 GM007266
6 · The paper itself

Abstract

unlabelledA detailed characterization of the dynamics and breadth of the immune response to an acute viral infection, as well as the determinants of recruitment to immunological memory, can greatly contribute to our basic understanding of the mechanics of the human immune system and can ultimately guide the design of effective vaccines. In addition to neutralizing antibodies, T cells have been shown to be critical for the effective resolution of acute viral infections. We report the first in-depth analysis of the dynamics of the CD8(+) T cell repertoire at the level of individual T cell clonal lineages upon vaccination of human volunteers with a single dose of YF-17D. This live attenuated yellow fever virus vaccine yields sterile, long-term immunity and has been previously used as a model to understand the immune response to a controlled acute viral infection. We identified and enumerated unique CD8(+) T cell clones specifically induced by this vaccine through a combined experimental and statistical approach that included high-throughput sequencing of the CDR3 variable region of the T cell receptor β-chain and an algorithm that detected significantly expanded T cell clones. This allowed us to establish that (i) on average, ∼ 2,000 CD8(+) T cell clones were induced by YF-17D, (ii) 5 to 6% of the responding clones were recruited to long-term memory 3 months postvaccination, (iii) the most highly expanded effector clones were preferentially recruited to the memory compartment, and (iv) a fraction of the YF-17D-induced clones could be identified from peripheral blood lymphocytes solely by measuring clonal expansion. IMPORTANCE: The exhaustive investigation of pathogen-induced effector T cells is essential to accurately quantify the dynamics of the human immune response. The yellow fever vaccine (YFV) has been broadly used as a model to understand how a controlled, self-resolving acute viral infection induces an effective and long-term protective immune response. Here, we extend this previous work by reporting the identity of activated effector T cell clones that expand in response to the YFV 2 weeks postvaccination (as defined by their unique T cell receptor gene sequence) and by tracking clones that enter the memory compartment 3 months postvaccination. This is the first study to use high-throughput sequencing of immune cells to characterize the breadth of the antiviral effector cell response and to determine the contribution of unique virus-induced clones to the long-lived memory T cell repertoire. Thus, this study establishes a benchmark against which future vaccines can be compared to predict their efficacy.

Indexed as

Base SequenceCell LineageFlow CytometryHumansImmunologic MemoryMolecular Sequence DataSequence Analysis, DNAT-Lymphocytes, CytotoxicVaccines, AttenuatedViral VaccinesWashingtonYellow fever virusVaccines, AttenuatedViral Vaccines

Identifiers

PMID25653453
PMCPMC4442358
OpenAlexW2131682431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.